USFDA completes inspection at Aurobindo Pharma’s Unit IV

14 Nov 2019 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Aurobindo Pharma’s Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad. The inspection was carried out between November 4, 2019 to November 13, 2019. At the end of the inspection, the company has been issued a Form 483 with 14 observations.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×